Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience

Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quarter and said its recently acquired assets could help accelerate revenue growth.

MarketBeat • Sep 15, 2026

Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

Biogen NASDAQ: BIIB executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.

MarketBeat • Sep 12, 2026

Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • Sep 9, 2026

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Zacks Investment Research • Sep 8, 2026

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Dravet.

Business Wire • Sep 3, 2026

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease

GlobeNewsWire • Sep 3, 2026

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

GlobeNewsWire • Sep 1, 2026

Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.

GlobeNewsWire • Aug 31, 2026

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Aug 28, 2026